VXX vs XBI
iPath Series B S&P 500 VIX Short-Term Futures ETN vs SPDR S&P Biotech ETF
VXX$17.91
iPath Series B S&P 500 VIX Short-Term Futures ETN
VIX short-term futures, hedge / speculation.
Expense: 0.89%Yield: 0.00%
XBI$156.41
SPDR S&P Biotech ETF
Equal-weight biotech stocks in the S&P Biotech Index.
Expense: 0.35%Yield: 0.35%
Quick take
- • XBI has the lower expense ratio at 0.35% vs 0.89% for VXX.
- • XBI pays a higher dividend yield (0.35%).
Side-by-side metrics
| Metric | VXX | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.89% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.00% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $566M | $10.92B |
YTD return | -28.15% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | -58.66 | 1.01 |
P/E ratio | — | — |
Last price | $17.91 | $156.41 |
Inception | — | — |
Issuer | Barclays | State Street |
VXX top holdings
Holdings data unavailable for VXX.
XBI top holdings
Top holdings · XBI
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
Sector breakdown · XBI
Financial Services0.6%
Healthcare99.3%
About VXX
VXX (iPath Series B S&P 500 VIX Short-Term Futures ETN) is VIX short-term futures, hedge / speculation. Managed by Barclays, the fund carries $566M in assets under management, an expense ratio of 0.89%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.